Literature DB >> 15932813

[Off label drug use in adult patients treated by anticancer chemotherapy].

Dominique Levêque1, Anne Cécile Michallat, Carine Schaller, Marlène Ranc.   

Abstract

Off-label drug use is supposed to be widespread in chemotherapy but very few studies have determined its extent in clinical practice. This prospective study evaluates the proportion of off-label anticancer drug use in terms of indications in a French teaching hospital. Adult ambulatory patient prescriptions were analysed by pharmacists in the year 2002. Data concerning the type of cancer and the indication of the antitumor agent were collected and compared with the official Summary of Product Characteristics in France. In the year 2002, 6,168 chemotherapy cycles (prescriptions) were administered to 1,206 patients. Four hundred and fifteen (6.7%) prescriptions presented a drug used in an off-label manner. Off label prescriptions were common in patients with hormone-refractory prostate cancer (57.6% of the courses for this type of tumor) and in patients with bladder cancer (37.6%). No off-label use was observed in patients with colorectal cancer. The drugs most commonly used in an off-label indication were docetaxel (29.1% of the off label prescriptions) and oxaliplatin (23.6%). Overall, in our hospital, the proportion of off-label use of anticancer agents in terms of indications in adult patients appears low.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932813

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  5 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.

Authors:  Jason D Wright; Alfred I Neugut; Elizabeth T Wilde; Donna L Buono; Jennifer Malin; Wei Y Tsai; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Licensing and labelling of drugs in a paediatric oncology ward.

Authors:  Henk van den Berg; Nanda Tak
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

4.  Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.

Authors:  Weilan Wang; Man Zhu; Daihong Guo; Chao Chen; Dongxiao Wang; Fei Pei; Liang Ma
Journal:  Iran J Public Health       Date:  2013-05-01       Impact factor: 1.429

5.  The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.

Authors:  Marta Herrero Fernandez; Raquel Molina Villaverde; Monica Arroyo Yustos; Fatima Navarro Expósito; Jose Luis Lopez Gonzalez; Maria Rosario Luque Infantes; Melchor Alvarez-Mon Soto
Journal:  Front Pharmacol       Date:  2019-10-23       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.